CLINICAL_TRIALS
trial_result
· 2011-07-06
Clinical Trial Update: 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response [Phase 3]
Summary
Phase 3 trial comparing 14-week versus 24-week hepatitis C treatment in genotype 2/3 patients with rapid virological response has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Ullevaal University Hospital | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED